Why the study?
Does apixaban reduce hospital length of stay and hospitalization costs in adult patients hospitalized with non-valvular atrial fibrillation compared to warfarin?
Does apixaban reduce hospital length of stay and hospitalization costs in adult patients hospitalized with non-valvular atrial fibrillation compared to warfarin?
In hospitalized patients with non-valvular atrial fibrillation, apixaban use is associated with a significantly shorter length of stay and lower hospitalization costs compared to warfarin.
No takes yet. Share an insight, caveat, or question.
May support apixaban consideration in hospitalized NVAF; extends observational data but leaves randomized confirmation open.
Xie et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: